Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 891 participants.
Also called NCT01785875
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 891 participants
- Sponsor
- Registry
-
NCT01785875 -
2012-002808-41
-
- Other papers using this trial's data
- One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01785875. Allocation not applicable; no masking; primary purpose treatment. Start 2013-07-31 (actual); primary completion 2015-07-01 (actual). Results posted on 2017-03-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
- Condition
- Hyperparathyroidism, Secondary
- Intervention (Drug)
- Etelcalcetide
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01785875- Content hash
6a2951e1f911483f6da15cb42913de618d9ca7fb7276dfcb568281caed8dc218